MedPath

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Phase 2
Completed
Conditions
Hepatitis B, Chronic
Interventions
Drug: ARB-001467
Other: Placebo
Registration Number
NCT02631096
Lead Sponsor
Arbutus Biopharma Corporation
Brief Summary

The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467

Detailed Description

Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Documented chronic HBV infection for ≥12 months prior to Screening Visit.
  • Quantitative HBsAg ≥1000 IU/mL at the Screening Visit.
  • Subjects currently receiving entecavir and/or tenofovir for ≥12 months and HBV DNA undetectable.

Key

Read More
Exclusion Criteria
  • Known co-infection with HIV, hepatitis C virus, and hepatitis D virus.
  • Receiving or planning to receive systemic immunosuppressive medications during the study or ≤2 months prior to the first dose of study treatment.
  • Receiving or planning to receive interferon during the study or ≤12 months prior to the first dose of study treatment.
  • Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.
  • Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the Screening Visit.
  • Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
0.4 mg/kg ARB-001467 or PlaceboPlaceboHBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
0.2 mg/kg ARB-001467 or PlaceboARB-001467HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
0.4 mg/kg ARB-001467 or PlaceboARB-001467HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
ARB-001467 or PlaceboARB-001467HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
ARB-001467 or PlaceboPlaceboHBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
0.2 mg/kg ARB-001467 or PlaceboPlaceboHBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
0.4 mg/kg ARB-001467ARB-001467HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
Primary Outcome Measures
NameTimeMethod
Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment.28 days post last infusion

To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy

Secondary Outcome Measures
NameTimeMethod
Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf) partial, AUCs, T1/2, volume of distribution (VD) and clearance (CL) -baseline through Day 85 or Week 36.Up to 36 Weeks

To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).Up to 36 Weeks

To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).Up to 36 Weeks

To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (cohort 1-3) and Week 36 (Cohort 4).Up to 36 Weeks

To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

Evaluate antiviral activity of ARB 001467 for up to 72 weeks after the first dose of study treatment.Up to 18 months

The proportion of subjects in each dose level cohort with ≥0.5 log10 HBsAg decrease from baseline at EOS, and for these subjects, the changes from baseline (expressed as percentage and log10 change) in the following virologic markers will be assessed throughout the study:

* Quantitative HBV surface antigen (HBsAg)

* Quantitative HBV surface antibody (HBsAb)

* Quantitative HBV DNA and HBV-RNA (viral load)

For the HBeAg positive cohort only:

- Quantitative HBV e antigen (HBeAg)

Trial Locations

Locations (4)

Monash Health, Gastroenterology and Hepatology

🇦🇺

Clayton, Victoria, Australia

Auckland Clinical Studies Ltd

🇳🇿

Auckland, New Zealand

The Alfred, Gastroenterology and Hepatology

🇦🇺

Melbourne, Victoria, Australia

Linear Clinical Research Ltd

🇦🇺

Nedlands, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath